1. Articles from ecancer


  2. 1-26 of 26
    1. Cancer in children adversely affects parents' income and employment

      "The researchers found that parents’ income from employment decreased significantly following a child’s cancer diagnosis, with an overall 21 percent reduction in mothers’ earnings and a 10 percent reduction in fathers’ earnings for the year of diagnosis when compared with control parents.  The relative reduction in income of mothers was evident up to six years post-diagnosis, whereas fathers’ income was reduced for two years post-diagnosis."

      Read Full Article
    2. Researchers describe a new type of cancer therapy

      Researchers describe a new type of cancer therapy

      "We tested RCn's tumour killing efficacy in cell lines of numerous cancers, including sarcomas, lymphoma and neuroblastoma," said Timothy Cripe, MD, PhD, principal investigator in the Center for Childhood Cancer and Blood Disease in The Research Institute at Nationwide Children's and senior author on the paper. "We observed anticancer activity of the RCn amines in all the cancer cell lines analysed."  Researchers found that RCn, and RC16 in particular, is 10 times more effective in harming tumour cells than regular cells. That means the low dose needed to kill cancer will have minimal effect on normal cells."

      Read Full Article
      Mentions: Chemotherapy
    3. Improving the long-term health of childhood cancer survivors

      Improving the long-term health of childhood cancer survivors

      "SIOPE together with all partners in the PanCareSurFup project strives to find solutions to the challenges they encounter on a daily basis with useful initiatives, such as the “Survivorship Passport” and its related guidelines for follow-up.  The current lack of information on many patients’ medical history becomes particularly critical as children become adults, or as they move to another country.  Moreover, a difficult relationship or a lack of understanding from doctors can characterise the survivor’s journey."

      Read Full Article
      Mentions: Treatment
    4. Gene often lost in childhood cancer crucial in cells' life or death decision

      "Our data strongly suggest that KIF1Bβ, which is localised on chromosome 1p36, might be such a neuroblastoma tumour suppressor gene", says principal investigator Susanne Schlisio at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet and Assistant Member at the Ludwig Institute for Cancer Research in Stockholm, Sweden.  Neuroblastoma tumours originate from the same transient progenitor cells -- neural crest cells -- that give rise to the nervous system along with other tissues.  Members of some families are at higher risk than others to develop tumours that originate from these cells due to mutations in specific genes. The research team ...

      Read Full Article
    5. Cancer-driving signals cause high-risk neuroblastoma

      Cancer-driving signals cause high-risk neuroblastoma

      "They showed that variants in the LIN28B gene generate abnormal signals that regulate another gene called RAN. The RAN gene, in turn, becomes overactive and produces higher levels of the RAN protein, causing cells to grow out of control in tumours. Acting in both direct and indirect ways, LIN28B also blocks tumour suppressor genes that normally put the brakes on cancer. The research suggests that signals originating in LIN28B ultimately promote another gene called AURKA, already known to play key roles in neuroblastoma and other cancers. All three genes, LIN28B, RAN, and AURKA , function as oncogenes--genes known to drive cancer ...

      Read Full Article
    6. Nature paper describes new molecular markers for high-risk neuroblastoma

      Nature paper describes new molecular markers for high-risk neuroblastoma

      "Both MYCN amplification and TERT rearrangements massively increased expression of TERT as well as enzymatic telomerase activity. Additionally, it was shown that high-risk tumours, even without any genomic alterations in MYCN or TERT, were prone to exhibiting a lengthening of telomeres.  Taken together, these findings suggest that most high-risk neuroblastomas are affected by either TERT rearrangements, MYCN amplification, or ATRX mutations, all of which lead to telomere lengthening, thereby providing a molecular, mechanistic definition of this neuroblastoma subtype.  By contrast, low-risk tumours are characterised by the absence of such alterations and by low TERT expression levels, which presumably renders the ...

      Read Full Article
      Mentions: MYCN ATRX
    7. SIOPE launches European Cancer Plan for Children and Adolescents

      SIOPE launches European Cancer Plan for Children and Adolescents

      "The SIOPE – MAC event will present the European Cancer Plan for Children and Adolescents – from the extensive consultation and consensus-building process leading up to its formulation and the prominent role of parents, patients and survivors, to the best ways towards implementation through joint efforts.  Collaborative models and enabling EU initiatives will be addressed, in particular on:

      • Eradicating inequalities in access to treatment, care, and expertise
      • Boosting innovation in medicines development 
      • Securing optimal organisation of follow up care for survivors"
      Read Full Article
    8. Improved care has extended the lifespan of childhood cancer survivors since the 1970s

      An analysis of over 34,000 participants in the federally funded Childhood Cancer Survivor Study shows improvement in late mortality achieved over three decades. Among five-year survivors, all-cause mortality at 15 years of diagnosis dropped from 12.4% to 6%. This improvement is attributed in part to changes in care that reduced the risk of mortality related to late effects of paediatric cancer treatment, such as subsequent malignancies and cardiac and lung disease.

      Read Full Article
    1-26 of 26
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video